To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
37 Current news
rss
ThromboGenics and BioInvent Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402
All further development of TB-402 will be stopped
07-06-2012
ThromboGenics NV and co-development partner BioInvent International announced the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban (Xarelto®; Bayer...
Cobra Biologics’ Expansion Continues
Three non-executive directors and two business development managers join to help expand the Company’s growing manufacturing business
14-02-2012
Europe AB and a board member of BioInvent International AB, KaroBio AB and Pharmalink AB. Elisabeth has significant senior management experience with Pharmacia Corporation, Octapharma AB and Diamyd Medical...
Anti-cancer activity of BioInvent's BI-505 demonstrated in animal model
15-12-2011
BioInvent International AB announced that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone...
Pharmalink AB elects Anders Wiklund as chairman and appoints Elisabeth Lindner to its board of directors
16-11-2011
. Lindner is a Director at BioInvent International AB and Karo Bio AB, and serves as Director of the Royal Swedish Academy of Engineering Science. She holds an MSc from Stockholm University and an M.B.A from...
BioInvent and ThromboGenics Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche
Two new studies now ongoing: phase Ib/II in patients with aggressive brain tumour and phase Ib in primary liver cancer
17-05-2011
BioInvent International AB and co-development partner ThromboGenics NV announced that their partner Roche has dosed the first patient in a phase Ib/II study with the novel antibody anti-cancer agent...
ThromboGenics and BioInvent Have Dosed the First Patient in Phase IIb Trial of TB-402 (Anti-Factor VIII) for Venous Thromboembolism (VTE) Prophylaxis
Trial to assess the benefits of partial Factor VIII inhibition in total hip replacement surgery patients
27-04-2011
ThromboGenics NV and co-development partner BioInvent International announce that the first patient has been dosed in a Phase IIb trial with their novel long-acting anticoagulant TB-402 (Anti...
First Patient Dosed in Phase II Clinical Trial for BioInvent's Cardiovascular Drug, BI-204
Trial start triggers US$ 15 million milestone from Genentech
16-03-2011
BioInvent International AB announced the dosing of the first patient in the phase II study of the Company’s antibody, BI-204. The product candidate is being developed for secondary prevention...
Positive TB-402 (Anti-Factor VIII Antibody) Phase II Data Published in Journal of Thrombosis and Haemostasis
14-02-2011
ThromboGenics NV and co-development partner BioInvent International announce today that the positive TB-402 (Anti-Factor VIII) Phase II trial results, evaluating the product’s efficacy and safety...
BioInvent extends antibody collaboration with Japanese pharmaceutical partner
Lead candidate for inflammation to progress into preclinical development
05-01-2011
BioInvent International AB announced that it has signed an agreement to extend its existing collaboration with an undisclosed Japanese pharmaceutical group. The extended collaboration comes...
BioInvent announces approval to start Phase II trial for its novel cardiovascular drug BI-204
12-11-2010
BioInvent International AB announced IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically...
Netmeeting
